Oncolys BioPharma Inc. (TYO:4588)
Japan · Delayed Price · Currency is JPY 4,110.00
+90.00 (2.24%)
Aug 27, 2026, 11:05 AM JST
Oncolys BioPharma Revenue
Oncolys BioPharma had revenue of 500.00M JPY in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 28.55M, down -9.04% year-over-year. In the year 2024, Oncolys BioPharma had annual revenue of 31.38M, down -50.21%.
Revenue (ttm)
28.55M
Revenue Growth
-9.04%
P/S Ratio
4,146.00
Revenue / Employee
679.67K
Employees
45
Market Cap
118.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38M | -31.65M | -50.21% |
| Dec 31, 2023 | 63.04M | -913.14M | -93.54% |
| Dec 31, 2022 | 976.18M | 333.69M | 51.94% |
| Dec 31, 2021 | 642.49M | 328.32M | 104.50% |
| Dec 31, 2020 | 314.18M | -989.67M | -75.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nxera Pharma | 33.43B |
| GNI Group | 26.53B |
| PeptiDream | 19.20B |
| Heartseed | 3.03B |
| Japan Tissue Engineering | 2.52B |
| AnGes | 962.00M |
| Cuorips | 128.00M |
| Healios K.K. | 59.00M |